Date: Oct 15, 2019 Source: (
click here to go to the source)
Mitokinin today announced that The Michael J. Fox Foundation has awarded the Company a $300,000 grant to advance its Parkinson's disease program.
"The Michael J. Fox Foundation has been an invaluable partner for us from our earliest days," said Nicholas Hertz, PhD, Mitokinin's Chief Science Officer. "We are gratified by their belief in the quality and potential impact of our work, and by their willingness to put the foundation's resources and relationships behind us as we try to develop our first-in-class, disease-modifying therapeutics for Parkinson's disease."
The grant monies will go toward supporting a collaboration with leading Parkinson's disease researcher Miratul Muqit, MD PhD, at the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee.
About Mitokinin
Mitokinin is late-preclinical stage biotechnology company developing PINK1-targeted therapeutics for Parkinson's disease. By selectively amplifying active-form PINK1 activity, Mitokinin believes it can address the cellular pathologies underlying Parkinson's disease and ultimately slow or halt the progression of the disease. Learn more at www.mitokinin.com.
